跳至主要内容
临床试验/NCT02594501
NCT02594501Unknown不适用

COBRA PzF Stenting to Reduce the Duration of Triple Therapy in Patients Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention

CeloNova BioSciences, Inc.78 个研究点 分布在 8 个国家目标入组 996 人开始时间: 2016年2月5日最近更新:
适应症

试验速览

阶段
不适用
入组人数
996
试验地点
78
主要终点
BARC class >=2 bleeding after hospital discharge (or beyond 14 days, whichever is "later").

研究概览

简要总结

The purpose of this study is to determine whether patients undergoing coronary intervention that also require oral anticoagulation, treatment with the COBRA PzF stent plus 14-day dual anti-platelet therapy (DAPT) has higher safety and non-inferior outcomes for thrombo-embolic events than compared with standard FDA-approved drug eluting stent (DES) plus 3 or 6-month DAPT.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients older than age 18 with ischemic symptoms (stable or unstable angina or NSTEMI without thrombosis of the target lesion on coronary angiography) or evidence of myocardial ischemia in the presence of ≥ 50% de novo stenosis located in native coronary vessels (max. 2 lesions in one or 2 separate vessels).
  • Patient receiving or with an indication for new treatment with long-term oral anticoagulation with a coumadin derivatives or non-vitamin K oral anticoagulants.
  • Written, informed consent

排除标准

  • Cardiogenic shock
  • Target lesion located in left main trunk
  • Bifurcation interventions with a planned 2-stent strategy
  • Vessel size too small for implantation of a 2.5 mm stent by visual estimation
  • Patient requiring staging PCI procedure within 6 months after the index procedure
  • Patients requiring DAPT for more than 2 weeks after the index procedure
  • Contraindications or allergy to cobalt, chromium, platinum, polyzene-F, everolimus, zotarolimus or the inability to take triple therapy for at least 6 months
  • Relevant hematologic deviations: platelet count <100x10^9 cells/L or >600x10^9 cells/L
  • Active bleeding; bleeding diathesis; recent trauma or major surgery in the last month; history of intracranial bleeding or structural abnormalities; suspected aortic dissection
  • Malignancies or other co-morbid conditions with life expectancy less than 12 months or that may result in protocol non-compliance
  • Pregnancy, present (positive pregnancy test), suspected or planned, breast feeding
  • Known allergy or intolerance to the study medications: ASA, clopidogrel, coumadin and its derivatives
  • Patient's inability to fully cooperate with the study protocol

结局指标

主要结局

BARC class >=2 bleeding after hospital discharge (or beyond 14 days, whichever is "later").

时间窗: 6 months

Composite of all cause death, myocardial infarction, definite and probable stent thrombosis or ischemic stroke

时间窗: 6 months

次要结局

  • Ischemic stroke(12 months)
  • Composite of cardiac death and myocardial infarction(12 months)
  • BARC class 3-5 bleeding(6 months)
  • Ischemia driven target lesion revascularization(12 months)
  • TIMI major bleeding; TIMI major and minor bleeding(6 months)
  • Health economic utility(12 months)
  • Composite of all cause death, myocardial infarction, definite and probable stent thrombosis, ischemia-driven target lesion revascularization or ischemic stroke(12 months)
  • Definite and probable stent thrombosis(12 months)
  • Acute Success Rates(procedure)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (78)

Loading locations...

相似试验